The Use of DREADDs to Deconstruct Behavior by Paul D. Whissell et al.
fgene-07-00070 May 12, 2016 Time: 16:35 # 1
REVIEW
published: 17 May 2016
doi: 10.3389/fgene.2016.00070
Edited by:
Robert Gerlai,
University of Toronto, Canada
Reviewed by:
Ilan A. Kerman,
University of Alabama at Birmingham,
USA
Arshad M. Khan,
University of Texas at El Paso, USA
*Correspondence:
Loren J. Martin
lj.martin@utoronto.ca
Specialty section:
This article was submitted to
Neurogenomics,
a section of the journal
Frontiers in Genetics
Received: 01 February 2016
Accepted: 12 April 2016
Published: 17 May 2016
Citation:
Whissell PD, TohyamaS andMartin LJ
(2016) The Use of DREADDs
to Deconstruct Behavior.
Front. Genet. 7:70.
doi: 10.3389/fgene.2016.00070
The Use of DREADDs to Deconstruct
Behavior
Paul D. Whissell1, Sarasa Tohyama2 and Loren J. Martin2*
1 Department of Psychology, University of Toronto, Toronto, ON, Canada, 2 Department of Psychology, University of Toronto
Mississauga, Mississauga, ON, Canada
A central goal in understanding brain function is to link specific cell populations to
behavioral outputs. In recent years, the selective targeting of specific neural circuits
has been made possible with the development of new experimental approaches,
including chemogenetics. This technique allows for the control of molecularly defined
subsets of cells through engineered G protein-coupled receptors (GPCRs), which
have the ability to activate or silence neuronal firing. Through chemogenetics, neural
circuits are being linked to behavioral outputs at an unprecedented rate. Further,
the coupling of chemogenetics with imaging techniques to monitor neural activity in
freely moving animals now makes it possible to deconstruct the complex whole-brain
networks that are fundamental to behavioral states. In this review, we highlight a specific
chemogenetic application known as DREADDs (designer receptors exclusively activated
by designer drugs). DREADDs are used ubiquitously to modulate GPCR activity in vivo
and have been widely applied in the basic sciences, particularly in the field of behavioral
neuroscience. Here, we focus on the impact and utility of DREADD technology in
dissecting the neural circuitry of various behaviors including memory, cognition, reward,
feeding, anxiety and pain. By using DREADDs to monitor the electrophysiological,
biochemical, and behavioral outputs of specific neuronal types, researchers can better
understand the links between brain activity and behavior. Additionally, DREADDs are
useful in studying the pathogenesis of disease and may ultimately have therapeutic
potential.
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INTRODUCTION
In recent years, the emergence of genetic techniques to selectively manipulate cellular activity
has revolutionized the neurosciences. Two of the most commonly used genetic techniques to
control cell activity are chemogenetics, which uses engineered G-protein coupled receptors that
are activated by otherwise inert drug-like small molecules, and optogenetics, which uses channels
that are activated by light (Boyden et al., 2005; Armbruster et al., 2007). The incorporation of
chemogenetics and optogenetics into animal models has greatly advanced our understanding of
neural circuits and redefined the drug development process. Beyond their use in exploratory
research, these techniques also have considerable translational potential. Both chemogenetics and
optogenetics have been applied in non-human primates and may ultimately have therapeutic utility
in humans, particularly in the treatment of behavioral disorders (Urban and Roth, 2015).
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Chemogenetic technology has been employed in many
subfields of neuroscience, but is perhaps most frequently used to
investigate the neural mechanisms of behavior. The accessibility
and versatility of chemogenetic technology has resulted in
an explosion of ‘end users’ and an increasing amount of
behavioral labs now include the chemogenetic technique in
their everyday ‘toolbox.’ Here, we summarize the practical
considerations for the use of chemogenetics, and contrast
this technique with optogenetics. Additionally, we review how
chemogenetic approaches have been used to interrogate a wide
range of behaviors, including associative learning, memory,
cognition, feeding, mood, and pain. Finally, we discuss the use of
chemogenetics in animal models of disease and comment on the
future potential of chemogenetics in translational research and
clinical settings.
Practical Considerations
Chemogenetic technology allows for the precise characterization
of specific cell types in the context of their native systems.
To study a particular cell subpopulation using chemogenetics,
engineered designer receptors must first be selectively expressed
in that cell population. Chemogenetics in the context of this
review refers to the designer receptors exclusively activated
by designer drugs (DREADDs) developed by Bryan Roth and
colleagues at the University of North Carolina (Armbruster et al.,
2007). DREADDs are modified muscarinic G-protein coupled
receptors (GPCRs). These designer receptors are typically
introduced into cells by viral vectors and they provide a lock-and-
key approach to selectively modulate cellular activity by chemical
means.
DREADD technology has been used to control the activity
of a wide range of cell types. The selective targeting of
DREADDs to a cell population can be achieved by using a
cell type-specific promoter to drive DREADD expression, and
the expression of this promoter can be further controlled using
a recombinase-based system. There are many viral constructs
encoding DREADDs that require genetic recombination to
produce functional designer receptors, most notably Cre-
dependent adeno-associated viruses (AAVs). The use of Cre-
dependent AAVs restricts DREADD expression to cells that
selectively express Cre. Given the wide range of transgenic
mouse lines in which Cre expression is restricted to a particular
cell type, Cre-dependent AAVs are an increasingly popular
method of selectively expressing DREADDs in specific cell
populations. In cases where a viral construct is employed,
spatial specificity of DREADD expression is further refined
via stereotaxic microinjection of the virus into a particular
location.
DREADDs possess a low affinity for endogenous ligands and
little constitutive activity, but may be activated by synthetic
compounds. Most DREADDs are selectively responsive to the
orally available drug, clozapine N-oxide (CNO; Armbruster et al.,
2007). Though CNO is a metabolite of the atypical antipsychotic
medication clozapine, the compound is biologically inert in
rodents and lacks appreciable affinity (Ki> 1 µM) for all relevant
native central nervous system targets (Armbruster et al., 2007).
The effect of CNO on a DREADD depends upon the signaling
cascade to which that DREADD is coupled. DREADDs, much
like endogenous GPCRs, are either coupled to an inhibitory (Gi)
or excitatory (Gq, Gs) signaling cascade. CNO activation of the
modified human M4 muscarinic DREADD, which is coupled
to Gi signaling, silences neuronal activity (hM4Di receptor;
Armbruster et al., 2007). Conversely, CNO activation of the
modified human M3 muscarinic DREADD receptor, which is
coupled to Gq signaling, elicits burst firing in neurons (Alexander
et al., 2009; hM3Dq receptor; see Figure 1).
The temporal properties of DREADD activation are
dependent upon the pharmacokinetic properties of their
agonists. Following peripheral administration of CNO, plasma
levels of the drug peak within 30 min and sharply decline
over the subsequent 2 h (Guettier et al., 2009). Though plasma
levels of CNO decline quickly, behavioral effects of the drug
may be evident for up to 6 h (Alexander et al., 2009). Thus,
DREADD technology is preferred in studies where the activity
of neurons must be manipulated over a longer time period
(hours to days). In contrast, a technique such as optogenetics
FIGURE 1 | Summary of modified human muscarinic (hM) and
Kappa-opioid receptor (KOR) designer receptors exclusively activated
by designer drugs (DREADD) subtypes. hM3Dq, human M3 - Gq
coupling; hM4Di, human M4- Gi coupling; KORD – Gi coupling. The
muscarinic receptors are activated by clozapine N-oxide (CNO), a metabolite
of clozapine and the KORD is activated by salvinorin B, an inactive, drug-like
metabolite of the KOR-selective agonist salvinorin A (SALA). The intracellular
signaling and neuronal activity that results from the activation of these
receptors is also depicted. Circles represent mutations in TMDIII and TMV for
muscarinic receptors whereas triangles represent mutations in the “message
domain” of TMII and extracellular end of TMVI for KORD.
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is strongly preferred for studies where neuronal activity
must be controlled over shorter time intervals (seconds to
milliseconds).
DREADD approaches are highly flexible in terms of drug
delivery. CNO is commonly administered via injection, but the
drug can also be mixed into food chow or drinking water (Urban
et al., 2016). The delivery of CNO via food or water may be
convenient in long-term studies, particularly if the experimenter
wishes to avoid repeated handling and/or injecting of animals.
Though food and water are less invasive routes of administration
for CNO, they are also less precise. It is difficult to control for the
amount of CNO ingested via these routes, as the intake of food
and water may fluctuate. An alternative method of delivering
CNO, which has yet to be widely used, is the implanted osmotic
minipump. This device could release a well-controlled systemic
dose of CNO over a long period of time.
Though CNO-dependent DREADDs have proven very useful
in rodent models, there is a strong interest in developing new
DREADDs with alternative properties for several reasons.
Although CNO is not subject to significant metabolic
transformation in mice and rats, a small fraction of the
drug is reverse metabolized to clozapine in humans, non-human
primates and guinea pigs (Jann et al., 1994; Chang et al., 1998;
Loﬄer et al., 2012). The conversion of CNO to clozapine in
several species limits the scope and translational potential of
CNO-dependent DREADDs. Recently, a novel DREADD has
been developed that incorporates an engineered kappa-opioid
receptor coupled to an inhibitory Gi-signaling cascade. This
kappa-opioid receptor DREADD (termed KORD) is insensitive
to endogenous ligands, including the dynorphins, which are
the natural ligands for kappa-opioid receptors. The KORD is
exclusively activated by the inert ligand, salvinorin B (SALB),
which is a semi-synthetic analog of the natural psychotropic
agent salvinorin A (Vardy et al., 2015). A comparison of the
chemical structures of DREADD agonists, and the compounds
from which these agonists are derived, is presented in Figure 2.
The development of more sophisticated DREADDs that offer
better control and specificity will increase the translational
potential of DREADD technology.
The existence of multiple DREADDs with different ligand
affinities also allows for another benefit: the incorporation of
multiple DREADDs into the same biological system (Vardy
et al., 2015; see Figure 3). In a recent study, excitatory
(hM3Dq) and inhibitory (KORD) DREADDs were expressed
within the same animal (Vardy et al., 2015). This ‘multiplexed’
approach permitted the bidirectional control of neuronal activity
and a more thorough interrogation of behavior. Importantly,
as the pharmacokinetic profiles of SALB and CNO differ –
SALB mediates rapid short-lasting effects (≈5 min) whereas
CNO mediates delayed long-lasting effects (≈1 h) – each
drug differentially affects the temporal dynamics of neuronal
activity (Vardy et al., 2015). Thus, CNO-based DREADDs and
SALB-based DREADDs may each provide unique information
about neuronal function. SALB-based DREADDs may be more
informative of how transient inactivation of neurons affects
behavior whereas CNO-based DREADDs may be informative
of how tonic activation of neurons influences behavior. Users
FIGURE 2 | Chemical structure of DREADD actuators. (A) The chemical
structures for clozapine and clozapine N-oxide (CNO) are shown. (B) The
chemical structures for salvinorin A (SALA) and salvinorin B (SALB) are shown.
CNO and SALB are otherwise biologically inert and are considered selective
DREADD actuators. CNO stimulation of hM3Dq- or hM4Di-expressing
neurons leads to neuronal excitation or inhibition, respectively (see text for
details). Activation of KORD by SALB leads to neuronal inhibition, albeit on a
quicker time scale than the activation of hM4Di by CNO. Note that CNO
differs from clozapine only in the presence of the N-oxide moiety and SALA
undergoes deacetylation to form SALB.
of DREADD technology should be aware that acute and tonic
activation of neurons are not equivalent and may have different –
even opposite – behavioral consequences. This was illustrated
in a recent study, wherein acute and chronic activation of
serotonergic neurons had different effects on mood (Urban et al.,
2016).
DREADDs and Optogenetics
In order to fully appreciate the utility of DREADD technology,
it is necessary to understand how this technique differs from
other approaches, most notably optogenetics. Here, we briefly
review some of the major differences between DREADDs and
optogenetics that have implications for the study of behavior. For
more detailed comparisons of these two techniques, the reader is
directed to several excellent reviews (Aston-Jones and Deisseroth,
2013; Krashes and Kravitz, 2014; Krook-Magnuson and Soltesz,
2015; McElligott, 2015; Lee and Kim, 2016).
A primary difference between DREADDs and optogenetics
is the degree of temporal specificity in controlling neuronal
activity. As mentioned previously, DREADDs are ideally suited
for prolonged modulation of cell activity in the range of
minutes–hours (Armbruster et al., 2007; Alexander et al., 2009).
Optogenetics, in contrast, can reversibly manipulate cell activity
in the range of milliseconds. With optogenetics, the experimenter
has direct control over the frequency of light stimulation and
therefore the frequency of neuronal activity. Many studies
utilize ‘physiologically relevant’ patterns of light stimulation
that model endogenous patterns of neuronal activity (Kim
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FIGURE 3 | Using DREADDs to deconstruct behavior. In order to determine whether neurons drive a particular behavior, a DREADD can be expressed by
microinjection into restricted cell populations. With two different DREADDs, responding to different exogenous ligands, the bidirectional control of neuronal activity is
possible. By activating the excitatory DREADD (hM3Dq, red neuron) via CNO, it is possible to see which cell populations control certain behaviors. Alternatively, this
same set of neurons can also express the inhibitory KORD (green neuron), which when activated by SALB will silence neuronal firing. Since CNO-activated
DREADDs operate on a long timescale (1–6 h) and KORD-activated DREADDs have a rapid time course (5–60 min), experimenters can now excite a particular set of
neurons and then rapidly inhibit them to provide conclusive evidence of their involvement in a given behavior.
et al., 2016). The difference in temporal resolution between
DREADDs and optogenetics is critical when deciding which
technique is best for an experiment. If a researcher is interested
in modulating neuronal activity during a brief behavioral state,
such as an episode of freezing behavior, optogenetics may be
most suitable. Alternatively, DREADDs might be more ideal
if the researcher wishes to modify neuronal activity over a
prolonged time period, such as during a 30 min period of restraint
stress.
DREADDs and optogenetics both have a relatively high
degree of spatial resolution, as both can be made cell-specific.
In optogenetic studies, researchers achieve an especially high
level of spatial resolution through controlled placement of
the optic fiber. In the case of DREADDs, a comparable
level of spatial specificity is only possible if there is restricted
delivery of the exogenous ligand to a particular brain area,
such as via intracranial microinjection. This approach can be
effective in dissecting specific pre- or post-synaptic mechanisms
(Vazey and Aston-Jones, 2014). An additional consideration
for the use of optogenetics is that the effects of the applied
light may not be restricted to the axons or terminals of
interest. Indeed, excitation of terminals with light may lead to
backpropagation of excitatory signals to the cell body (Grossman
et al., 2013).
DREADDs offer many of the same advantages as optogenetics,
but are arguably easier to implement. As mentioned above,
the experimenter has considerable flexibility in a DREADD
study, and may administer CNO via several routes (injection,
food, water, or pump). In contrast, optogenetic studies require
specialized instrumentation to administer light, including
waveform generators, optic fibers and other devices (Zhang et al.,
2010). In optogenetic studies, the animal often has a tethered
implant, which may make measurement of certain behaviors
difficult.
Both DREADDs and optogenetics have inherent advantages
and disadvantages. The technique that is most useful depends
upon the experimental question and the resources available.
These techniques should be considered complimentary, not
competitive, and can even be employed within the same
experimental design. It is important to note that most studies
have found few significant differences comparing DREADD and
optogenetic approaches (Krashes et al., 2011; Carter et al., 2013;
Zhan et al., 2013; Siuda et al., 2016); however, there are some
exceptions to this (Carreno et al., 2015).
Frontiers in Genetics | www.frontiersin.org 4 May 2016 | Volume 7 | Article 70
fgene-07-00070 May 12, 2016 Time: 16:35 # 5
Whissell et al. Deconstructing Behavior with DREADDs
INTERROGATION OF BEHAVIOR USING
DREADDs
Neuroscientists routinely express DREADDs in specific brain
regions, usually via viral microinjections. Importantly, DREADD
expression in the brain is also possible without viral injection
or invasive surgery. Recently, transgenic mice have been
generated that constitutively express DREADDs in specific
cellular populations. Notably, a mouse model has been developed
that exclusively expresses hM3Dq in glial fibrillary acidic
protein+ (GFAP+) glial cells (Agulhon et al., 2013), which are
non-neuronal cells that play an important support function in
the nervous system. The activation of hM3Dq in GFAP+ glial
cells increased heart rate and blood pressure in a manner that
was not dependent upon intracellular Ca2+ release. Others have
shown that stimulating glial cells by activating hM3Dq receptors
with CNO generated neurogenic contractions in the ileum and
colon, suggesting that enteric glial cells may play a critical
role in controlling gut reflexes (McClain et al., 2015). Another
study has shown that selectively activating glial cells using
DREADDs hinders cocaine-seeking behavior in rats (Scofield
et al., 2015). DREADDs have also been useful in investigating
other non-neuronal cells besides glia, such as cardiac cells
(Kaiser et al., 2015), breast cancer cells (Yagi et al., 2011),
pancreatic β-cells, and hepatocytes (Hua Li et al., 2013). Although
DREADDs have been used to study non-neuronal cells, the
current review will focus exclusively on the use of DREADDs in
neurons.
A novel DREADD-based method for studying neural circuits
in freely moving animals is the “DREAMM” (DREADD-assisted
metabolic mapping) technique (Michaelides et al., 2013; Urban
et al., 2016). This method combines DREADD technology with
behavioral µPET imaging to generate whole-brain metabolic
maps. The initial study describing the utility of DREAMM
used herpes simplex virus (HSV) vectors to express hM4Di
receptors into specific populations of medium spiny neurons
(MSN) in the nucleus accumbens. Next, in order to determine the
whole brain consequence of MSN inhibition, rats were scanned
using µPET following CNO administration. The inhibition
of MSNs was highly associated with increased activity in the
primary components of the limbic system including the ventral
palladium, amygdala, entorhinal cortices, and hippocampus. In
contrast, MSN inhibition also led to significant decreases in
activity in the ipsilateral sensory cortex, globus pallidus, and
contralateral piriform cortex. Overall, these findings identified
distinct neural activity associated with MSN inhibition and
emphasized that impairments in the nucleus accumbens pathway
have profound bottom-up effects on cortical activity, particularly
in the limbic system (Michaelides et al., 2013). DREAMM
has the potential to quantitatively delineate discrete changes
in whole-brain neuronal circuits in vivo and assess cell-type–
specific whole-brain neuronal circuits during the awake state.
Overall, DREAMM fills a technological niche, but can also
be applied to many areas of neuroscience to advance our
understanding of whole-brain neural networks and functional
connectivity.
Recently, chemogenetic technology has been extended from
rodents to monkeys. In one remarkable study, hM4Di receptors
were used to disrupt the connections between the rhinal
and orbitofrontal cortices (OFC) (Eldridge et al., 2016). The
disruption of this pathway resulted in diminished sensitivity
to differences in reward value. These results are an important
extension of previous findings (Clark et al., 2013), and illustrate
the translational potential of DREADD technology.
With the recent surge in studies using DREADD techniques,
there exists a plethora of papers that provide further insight
into the neural mechanisms of various behaviors (Ferguson
and Neumaier, 2012; Lee et al., 2014; Urban and Roth, 2015;
Roth, 2016; Smith et al., 2016). An excellent review was recently
published that highlights DREADD applications in behavioral
neuroscience (Smith et al., 2016). In their review, Smith et al.
(2016) briefly highlight the use of DREADDs to study learning,
memory and drug addiction with a particular emphasis on
strategies that allocate specific neurons to these behaviors.
Herein, we expand upon this and highlight key studies that use
DREADDs to deconstruct a broad range of behaviors including
learning, memory, mood, feeding, and pain. Based on these
findings, we extrapolate the therapeutic value of DREADDs for
drug discovery and treating various disease states.
Associative Learning
Understanding the mechanisms of learning is a longstanding
goal of neuroscience, and this pursuit has been greatly facilitated
by DREADD techniques. Several recent studies have used
DREADDs to investigate associative learning (Robinson et al.,
2014; Yau and McNally, 2015), a process thought to be involved
in behavioral tasks such as sensory preconditioning and fear
conditioning.
Sensory preconditioning is a type of learning that requires
forming stimulus-stimulus associations (Robinson et al., 2014).
While it is widely accepted that preconditioning involves the
hippocampus (Yu et al., 2014), it is unclear which other regions
participate. Robinson et al. (2014) investigated whether the
retrosplenial cortex (RSC), a structure interconnected with the
hippocampus, is involved. In their model, hM4Di receptors were
selectively expressed in the neurons of the RSC. First, animals
were trained on a sensory preconditioning trial, wherein a light
and tone stimulus were presented together (light-tone pairing).
Thereafter, during a conditioning trial, the light stimulus was
presented with food (light-food pairing). Animals that acquired
the light-food association demonstrated a conditioned food-
seeking response to light. Further, animals that also acquired
the light-tone association during the sensory preconditioning
trial further showed a conditioned food-seeking response to
the tone stimulus – even though the tone had never been
paired with food. It was found that injection of CNO during
the preconditioning trial, which inhibited hM4Di-RSC neurons,
reduced the conditioned food-seeking response to the tone.
Accordingly, the authors concluded that sensory preconditioning
requires activity in the RSC.
New associative learning is thought to occur whenever a
predicted outcome for an event differs from the actual outcome –
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a ‘prediction error’ (Schultz and Dickinson, 2000). Animals,
much like humans, appear to best recall their ‘mistakes,’ and
demonstrate learning following errors in predicting outcomes.
The neural circuitry of prediction error has been studied using
DREADDs by Yau and McNally (2015), who examined the
contribution of the dorsal medial prefrontal cortex (dmPFC)
by expressing hM3Dq receptors in pyramidal neurons within
this region (Yau and McNally, 2015). First, hM3Dq-dmPFC
mice underwent a fear conditioning trial wherein a tone (CS1)
was paired with a footshock (CS1-shock pairing). As a result,
mice exhibited strong conditioned fear to CS1. Subsequently,
the mice were re-trained on the task, only the footshock was
now paired with the simultaneous presentation of the tone
(CS1) and a light (CS2) stimulus (CS1 + CS2-shock pairing).
While animals maintained a conditioned fear response to CS1
after this training protocol, they did not acquire a conditioned
fear response to CS2. This ‘blocking’ of conditioning to CS2 is
thought to occur because of the lack of prediction error – CS1 was
already a strong predictor of an impending foot shock, thus the
CS1+ CS2 combination generated little prediction error for CS2.
Interestingly, the activation of hM3Dq-dmPFC neurons with
CNO during the combined stimulus trial (CS1+ CS2) prevented
the blocking of fear conditioning to CS2. This result implies
that the excitation of dmPFC neurons can facilitate learning
new associations, perhaps by altering prediction error during
conditioning trials.
Memory
As well as studying the mechanisms of associative learning,
DREADD approaches have also been applied to dissect the
neural substrates of memory. In the brain, acquired memories
are represented by the collective activity of discrete ensembles
of neurons, referred to as memory traces (Tonegawa et al.,
2015). Of late, the physiological factors governing the encoding,
consolidation and updating of memory traces have been
extensively studied using DREADD approaches.
In particular, DREADDs have afforded considerable insight
into how memory traces are encoded (Sano et al., 2014; Yiu
et al., 2014). Most traces involve only a fraction of neurons
in a given brain region (∼10–30% of lateral amygdala neurons
may represent a fear memory, for example) and the process
by which neurons are included is thought to be competitive.
Using DREADD and other techniques, Yiu et al. (2014) addressed
whether the excitability of neurons during encoding affected their
probability of being incorporated into a memory trace. In testing
this possibility, Yiu et al. (2014) selectively expressed hM3Dq
receptors in lateral amygdala neurons and injected mice with
CNO prior to training in a fear conditioning task. If excitability
were a factor in determining the composition of the memory
trace, then CNO treatment during training should increase the
likelihood that hM3Dq+ neurons are incorporated into the trace.
Indeed, the authors observed this finding: CNO injection before
training greatly increased the probability that hM3Dq+ neurons
were active during retrieval of the fear memory, suggesting
that these neurons represented the fear memory trace. To
further verify this interpretation, the authors tested whether
reactivation of these hM3Dq+ neurons resulted in the expression
of fear. In hM3Dq+ animals given CNO during training, the
injection of CNO led to fear expression even in absence of the
conditioned stimuli normally required to elicit this response.
These findings strongly suggest that the neurons that are most
excitable during fear conditioning are incorporated into the
fear memory trace. Interestingly, another lab used DREADD
technology to demonstrate that similar principles govern the
assembly of memory traces for conditioned taste aversion in the
insular cortex (Sano et al., 2014).
The prolonged process of memory consolidation follows
memory encoding. Recently, the timeline for the consolidation
of contextual fear memory was investigated using DREADD
techniques (Zhu et al., 2014). In this study, hM4Di receptors were
selectively expressed in CAMKIIα neurons in the hippocampus.
Mice underwent training in the fear conditioning task and were
subsequently given an injection of CNO at either 0–4 h or 6–
10 h after training. Strikingly, mice given an injection 0–4 h after
training but not 6–10 h after training demonstrated impaired
contextual fear conditioning. Surprisingly, the authors found that
the inhibition of CAMKIIα neurons in the ventral hippocampus
(vHPC) impaired the consolidation of contextual fear memory –
inhibiting neurons in the dorsal hippocampus had no effect.
These results suggest that the ‘window’ for memory consolidation
of contextual fear memory in the vHPC is within 6 h of training.
Similar rules appear to govern the consolidation of other memory
traces, including those associated with drugs of abuse such as
cocaine (Shi et al., 2015).
DREADD techniques have also been applied to study the
time-dependent reorganization of memory (Richards et al.,
2014). Over time, related memories are thought to collectively
form ‘schemas’ which are defined by the concepts that these
memories share, and this process likely involves the mPFC
(Brod et al., 2015). Richards et al. (2014) tested this theory
using an innovative approach. In the water maze task, mice
were trained to navigate toward several platform locations over
a series of trials, with all locations being clustered in one
region of the maze. This paradigm was thought to encourage
the development of a spatial schema that would allow mice
to reliably predict the location of the platform. At 1 and
30 days after this protocol, the ability of mice to acquire novel
platform locations consistent or inconsistent with this schema
was assessed. Congruent with the idea that schemas develop
over time, mice tested 30 days after training more efficiently
navigated toward a schema-consistent platform. Interestingly,
mice tested 30 days after training also demonstrated better recall
of a schema-inconsistent platform location during a probe trial.
The authors speculated that mice tested 30 days after training
exhibited stronger recall of the schema-inconsistent platform
because of high prediction error during acquisition of its location.
To test whether the mPFC was important for the enhanced recall
of the schema-inconsistent platform location, the authors used
DREADD techniques. In mice with hM4Di receptors selectively
expressed in PFC neurons, the application of CNO during the
acquisition of a schema-inconsistent platform location reduced
subsequent recall of this location in a probe trial. These results
suggest that the mPFC is important to spatial schemas and also
support the notion that the mPFC contributes to learning as
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a result of prediction error [as suggested by Yau and McNally
(2015)].
Reward-Guided Behaviors
DREADDs have also been applied to study more general
processes, including reward-guided behaviors (Chang et al.,
2015; Ward et al., 2015). Typically, animals will form a strong
association between a reward and any cue that is present at the
time the reward is delivered (reward-cue pairing). Subsequently,
the presentation of a reward-paired cue will elicit a reward-
seeking response toward that cue. For example, if a lever
(cue) is extended whenever food (reward) is presented, an
animal will approach and interact with the lever whenever it is
presented (reward-seeking behavior). This behavior, termed sign
tracking, occurs even though the lever itself is not rewarding
and manipulating the lever is not required for the reward to
be obtained. Sign tracking is thought to occur because the
incentive value of the reward has been transferred to the cue,
but its mechanisms are poorly understood. Using DREADD
techniques, Chang et al. (2015) demonstrated that sign tracking
importantly involves the ventral pallidium (VP) of the brain. In
their experiment, a lever (CS+) was presented in conjunction
with a food reward. As a result, animals demonstrated a sign-
tracking response (lever pressing) whenever the lever is extended.
To directly manipulate VP activity, neurons of the VP were
transfected with hM4Di receptors. Thirty minutes prior to the
acquisition period, when animals learn to pair the CS+ with the
reward, CNO was injected to inactivate the VP. Interestingly,
CNO injection impaired the ability to acquire lever pressing in
response to the CS+. These results demonstrated an important
role of VP neurons in the acquisition of sign-tracking.
Evaluating the reward probability of an action is an important
factor in decision-making, and the OFC is thought to play a
central role in this process (Ward et al., 2015; Eldridge et al.,
2016). Ward et al. (2015) studied the role of the OFC in this
process using DREADD techniques. The authors generated mice
in which hM4Di receptors were expressed on OFC neurons
so that the activity of the OFC could be transiently inhibited.
In this study, animals were taught that food rewards could be
obtained via lever-pressing in two situations: high probability
of reward and low probability of reward. Normally, animals
were more accurate in obtaining food rewards in the high
probability condition than in the low probability condition. This
finding suggested that animals could discriminate between the
reward probabilities and tailored their responses accordingly.
When CNO was injected during testing, this discrimination
between high and low reward conditions was not evident, and
similar accuracy of responses was observed in both conditions.
Interestingly, involvement of the OFC in reward-guided behavior
has also been demonstrated using DREADD techniques in non-
human primates (Eldridge et al., 2016).
Although reward-mediated behaviors have been extensively
studied using DREADDs, this field of research should be
complimented with a technique where precise temporal control
is achievable, such as optogenetics. Decision-making operates
on a millisecond timescale, and the ability to rapidly modulate
neuronal activity with optogenetics may offer more insight
into this process. Optogenetic manipulation of neuronal activity
may change the decision-making process such that spilt-second
decisions and behavioral outcomes are rapidly and bidirectionally
altered.
Feeding and Energy Expenditure
Given the immense heterogeneity that exists in the brain, it is
absolutely essential to have tools that selectively target specific
cell types. The neurons of the hypothalamus are diverse and
control a large variety of behaviors, including feeding. With the
development of techniques such as DREADDs and optogenetics,
research into the neural circuitry of feeding behavior has made
impressive progress.
Bradford Lowell, along with others including Michael Krashes,
Scott Sternson, and David Olsen, have been at the forefront of
using DREADD and optogenetic approaches to dissect feeding
circuits (Krashes et al., 2011, 2013; Atasoy et al., 2012; Kong
et al., 2012). Their research has largely focused upon how
feeding behavior is regulated by agouti gene-related peptide
(AgRP)-expressing neurons in the arcuate nucleus (ARC) of the
hypothalamus. DREADD-mediated stimulation of ARC AgRP-
neurons using hM3Dq receptors increases food intake, resulting
in weight gain, less energy expenditure and enhanced fat storage
(Krashes et al., 2011, 2013, 2014; Atasoy et al., 2012; Denis
et al., 2015). A single injection of CNO (0.3 mg/kg) is sufficient
to enhance feeding behaviors over several hours. Additionally,
activation of AgRP neurons enhances feeding in calorically
replete mice that have otherwise no motivation to consume food
(Krashes et al., 2011).
With a sophisticated combination of mouse genetics and
DREADDs, Krashes et al. (2013) were able to demonstrate
that GABA and/or neuropeptide Y (NPY) is required for the
rapid stimulation of feeding. Further, the authors showed that
AgRP, through action on melanocortin 4 receptors (MC4Rs),
is sufficient to induce feeding over a delayed yet prolonged
period. Krashes et al. (2013) used a Cre-dependent AAV to
express hM3Dq receptors in the AgRP neurons of triple knockout
mice that lacked GABA release in these cells, as well as the
genes for NPY and MC4Rs (Agrp-Ires-Cre; Mc4r−/−; Vgatflox/flox;
Npy−/−). This study has helped to elucidate the neurochemical
mechanisms of AgRP neurons in controlling the distinct phases
of eating.
These reports, though highly informative, represent only the
“tip of the iceberg” in terms of DREADD-based research into
feeding and energy expenditure. In addition to AgRP neurons,
neurons expressing rat insulin promoter (RIP) have been linked
to energy expenditure. The disruption of GABAergic synaptic
transmission in RIP-Cre neurons of the ARC has been shown to
reduce energy expenditure and increase obesity in mice (Kong
et al., 2012). Additionally, mice with disrupted transmission
were extremely sensitive to high fat diet-induced obesity, most
likely due to defective diet-induced thermogenesis. When RIP-
expressing neurons were activated using hM3Dq receptors,
energy expenditure significantly increased but food consumption
was unaffected (Kong et al., 2012). It was concluded that GABA
plays an important role in regulating energy expenditure, but not
feeding behavior.
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Lastly, activation of pro-opiomelanocortin (POMC)-
expressing neurons in the ARC and the nucleus tractus solitarius
(NTS) using hM3Dq receptors has been shown to inhibit feeding
behavior (Zhan et al., 2013). Whereas NTS POMC neurons
induced appetite suppression via acute activation, ARC POMC
neurons required prolonged activation. These results suggest
that POMC neurons in the brainstem and hypothalamus regulate
satiety differently. Through the use of transgenic mouse models
and molecular tools that can monitor neural activity in freely
moving mice, the ambitious goal of deconstructing the complex
neural networks responsible for feeding behavior is fast becoming
a reality.
Mood
DREADD techniques are increasingly being applied to study
mood disorders. Disorders of anxiety and depression are
among the most prevalent mental health conditions, and carry
with them a significant burden of disease (World Health
Organization [WHO], 2008). A continual barrier in the treatment
of these chronic and debilitating disorders is that we do not
understand their underlying neural mechanisms. In determining
the neurological bases of mood disorders, DREADD techniques
have been a major asset.
One of the greatest challenges in treating mood disorders
has been understanding the complex role that is played by
the neurotransmitter 5-hydroxytryptamine (serotonin). The
serotonergic system, which includes the transmitter as well as
its receptors and transporters, plays a pivotal role in mood
regulation and is often disrupted in mood disorders. In the
treatment of anxiety disorders and severe cases of depression,
selective serotonin reuptake inhibitors (such as fluoxetine) are
commonly prescribed. The precise mechanism by which these
drugs are therapeutic remains the subject of much debate,
but is thought to involve both acute and chronic changes in
serotonergic activity.
In understanding the contribution of the serotonergic system
to mood, DREADD techniques have proven useful (Teissier et al.,
2015; Urban et al., 2016). In one recent study, the effect of
bidirectionally modulating the activity of serotonergic neurons in
the raphe nuclei was investigated (Teissier et al., 2015). This study
utilized Pet1-Cre mice, in which the expression of Cre is restricted
to Pet1-expressing neurons, which are primarily serotonergic
neurons of the mid-hindbrain. These Pet1-Cre mice were
subsequently crossed with one of two Cre-responsive DREADD
mouse lines (RC:PDi or RC:PDq) to generate transgenic mice that
expressed either hM3Dq receptors (Pet1-Cre; RC:PDq mice) or
hM4Di receptors (Pet1-Cre; RC:PDi mice) in raphe serotonergic
neurons. Interestingly, the authors found that CNO injection in
otherwise healthy hM3Dq mice increased anxiety-like behavior
in the open field and elevated plus task maze tasks. Conversely,
the injection of CNO in hM4Di mice had no effect. These results
suggest that acute enhancement of serotonergic activity, but not
inhibition, is anxiogenic.
Additionally, the authors investigated whether the effects
of acutely manipulating raphe serotonergic activity were
affected by changes in neurophysiology (Teissier et al., 2015).
Notably, depressed patients exhibit substantially different
neurophysiology relative to non-depressed individuals (Kohler
et al., 2016), and may respond differently to manipulation of
raphe serotonergic activity. To test the possibility that the effects
of raphe serotonergic activity may change in depression, the
authors conducted a similar series of experiments in a mouse
model of depressive-like behavior (Teissier et al., 2015). In this
model, mice were given fluoxetine during the perinatal period
(from postnatal days 2 to 11) before being subjected to behavioral
experiments in adulthood. These fluoxetine-treated animals,
termed PNFLX mice, exhibit a depressive-like phenotype.
Surprisingly, CNO treatment in PNFLX mice with expression of
hM4Di receptors in serotonergic neurons reduced depressive-
like behavior. This effect contrasts with the effect of serotonergic
neuron inhibition in healthy control mice, which is minimal.
The authors speculated that different effects of manipulating
serotonergic neurons between healthy mice and PNFLX mice
may be explained by comparative differences in the balance of
serotonergic activity. In healthy mice, stimulation via hM3Dq
activation may disrupt normal serotonergic activity and impede
behavior. In contrast, in depressed mice, inhibition via hM4Di
activation may normalize hyperserotonergic activity and rescue
behavior.
Additionally, the temporal dynamics of serotonergic activity
were shown to be an important factor in mood regulation,
as short- and long-term activation of serotonergic neurons
had contrasting behavioral effects (Urban et al., 2016). In
this study, the expression of hM3Dq receptors was restricted
to adult serotonergic neurons in the dorsal raphe nucleus
(DRN). Short-term activation of DRN neurons, via CNO
injection 30 min before behavioral testing, increased anxiety-
like behavior and marginally reduced depressive-like behavior.
Conversely, long-term activation of the serotonergic system,
via the administration of CNO in the drinking water for
3 weeks prior to behavioral testing, reduced depressive-like
behavior without affecting anxiety. These findings illustrate the
stark differences between short- and long-term modulation of
serotonergic activity. Additionally, these results shed light on the
paradoxical increase in anxiety that is sometimes observed after
commencing antidepressant treatment (the so-called ‘jitteriness
syndrome’), which often dissipates followed continued treatment.
Additionally, the finding that long-term CNO treatment is
required to reduce depressive-like behavior is consistent with the
observed treatment course of antidepressants, which often take
weeks to show positive effects.
DREADD techniques have also been applied to study
the mechanisms by which drugs exert their antidepressant
effects (Carreno et al., 2015). The anesthetic drug ketamine,
an N-methyl-D-aspartate antagonist, has recently attracted
considerable attention for its rapid antidepressant effects.
Currently, the mechanism of these effects is unknown. In a
recent study, Carreno et al. (2015) demonstrated that afferent
connections from the vHPC to the mPFC were critical for
the long-term antidepressant effects of ketamine. In the forced
swim test, mice given ketamine show less immobility and more
swimming and climbing relative to controls, a result indicative of
decreased depressive-like behavior. The long-term antidepressant
effects of ketamine were abolished when the connections from
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the vHPC to the mPFC were blocked via lidocaine infusion.
Using DREADD techniques, the authors showed that the selective
activation of vHPC terminals in the mPFC had antidepressant
actions strikingly similar to the effects of ketamine. In mice
expressing hM3Dq receptors selectively on vHPC terminals in
the mPFC, CNO injection reduced immobility and increased
swimming and climbing in the forced swim test. Interestingly,
the authors obtained an entirely different result when using an
optogenetic approach to activate these vHPC-mPFC connections.
Optogenetic stimulation of channelrhopdosin2-expressing vHPC
terminals in the mPFC failed to enhance immobility, and did not
appear to have an antidepressant effect. These results not only
highlight the usefulness of DREADD techniques in dissecting
neural circuitry of mood, but also are an important reminder that
optogenetic and DREADD approaches may sometimes differ.
Other DREADD studies have revealed an important
contribution of inhibitory circuitry in the mPFC to mood
regulation (Perova et al., 2015). The inhibitory neurotransmitter
γ-aminobutyric acid (GABA) is thought to be centrally involved
in mood regulation and disruptions of the GABAergic system
are often observed in mood disorders (Luscher et al., 2011;
Whissell et al., 2014). Recently, several studies have utilized
DREADD techniques to examine the contribution of GABAergic
interneurons to mood. Perova et al. (2015) used DREADD
techniques to examine the role of parvalbumin (PV)-expressing
GABA neurons in the development of learned helplessness, a
model of depression. In animals showing learned helplessness,
PV-GABA neurons in the mPFC receive less excitatory input, a
finding that suggests that reduced PV-GABA neuron activity may
facilitate learned helplessness. To test this hypothesis, the authors
selectively expressed hM4Di receptors in PV-GABA neurons
of the mPFC in order to inactivate these cells. Indeed, Perova
et al. (2015) observed that CNO treatment in hM4Di-PV-GABA
mice promoted learned helplessness, verifying that reductions
in PV-GABA neuron activity are associated with dysregulated
mood.
In a further study, the contribution of somatostatin (SST)-
expressing GABA neurons in the mPFC to emotional behavior
was investigated (Soumier and Sibille, 2014). As GABAergic
transmission tends to be reduced in mood disorders, the authors
were specifically interested in the effects of inhibiting SST-
GABA neuron function. To this end, they selectively expressed
hM4Di receptors in SST-GABA neurons in the mPFC (Soumier
and Sibille, 2014). As mood disorders involve both acute and
prolonged disruptions of GABAergic activity, the effects of
both short-term and long-term inhibition of SST-GABAergic
function on emotionality were investigated. Emotional behavior
was examined using a combination of assays, including the
elevated plus maze, open field, novelty-suppressed feeding,
sucrose preference and cookie tests. When SST-GABA neurons
were acutely inhibited via CNO injection 30 min prior to
behavioral testing, anxiety-like behavior and overall emotionality
was increased. The effect of long-term inhibition of SST-GABA
neurons was strikingly different. In the long-term treatment
regime, CNO was injected twice per day over a period of 3 weeks.
Surprisingly, chronic inhibition of SST-GABA neuron function
decreased overall anxiety-like behavior and emotionality. These
results highlight the value of DREADD techniques, which are
ideally suited to study behavioral changes over a long time
window.
Several studies have also employed DREADD techniques to
examine the contribution of dopamine (DA)-expressing neurons
to mood regulation (Zhong et al., 2014; Fritz et al., 2015).
Notably, DA-expressing neurons may play an important role
in the affective changes in other conditions, including systemic
inflammation. When inflammation is significant, such as during
illness, individuals often report impaired cognitive function and
depressed mood. Recently, DREADDs were used to explore the
contribution of DA-expressing neurons to the depressed mood
that is linked to systemic inflammation (Fritz et al., 2015).
Depressed mood was modeled in animals using the conditioned
place aversion task. When a particular location is paired with
an unpleasant experience, such as systemic inflammation, that
location becomes less preferred (more aversive) relative to
other neutral locations. It was observed that the excitation of
DA-expressing neurons in the ventral midbrain blocked the
establishment of conditioned place aversion.
The neural mechanisms governing anxiety, or more
specifically fear, have also been studied using DREADD
techniques. Importantly, animals have the capacity for both
innate fears (e.g., to predators) and learned fear (e.g., to stimuli
associated with aversive experiences). In certain situations,
animals are faced with only two options for action; one of these
options may elicit innate fear whereas another may elicit learned
fear. In these cases, animals must suppress either innate fear or
learned fear in order to select the best course of action (they must
choose between ‘the lesser of two evils’ in order to survive). The
ability to prioritize one fear over the other fear is thought to be
mediated by the amygdala of the brain. Recently, Isosaka et al.
(2015) demonstrated that serotonin type 2A (5HT2A)-receptor
expressing cells in the central amygdala are centrally involved
in the hierarchal organization of fear responses. Inhibition of
5HT2A cells with hM4Di receptors results in the suppression of
learned fear and the enhancement of innate fear.
Pain
Recently, DREADDs have been used to investigate the brain and
spinal circuits that underlie pain behaviors. Pain is a complex,
subjective phenomenon that causes feelings of physical and
emotional discomfort; its conditions are heterogeneous and the
underlying aetiologies, mechanisms, and sites of symptoms are
diverse. Within the last 50 years, few effective treatments for
chronic pain have emerged, largely because the mechanisms
of these disorders are incompletely understood. This lack of
insight is astounding when we consider that chronic pain affects
approximately 25% of the population (Elliott et al., 1999). Since
pain is the most common reason for seeking medical attention,
the clinical and translational significance of DREADDs has
potential to greatly progress the field. Despite the promising
implications of DREADD technology, there are only a limited
number of studies that use DREADDs to dissect pain circuits
(Bourane et al., 2015; Jurik et al., 2015; Peirs et al., 2015).
However, with the ease of implementing DREADD technology
in the laboratory, the pain field is likely to see a surge in the
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use of DREADDs. This development may ultimately lead to a
better understanding of pain circuits and the identification of new
therapeutic targets.
Recently, the laboratory of Rebecca Seal was able to
demonstrate that specific microcircuits within lamina III of the
dorsal horn of the spinal cord encode mechanical pain sensitivity
differently depending on the injury (Peirs et al., 2015). Neurons
in these circuits are required for mechanical pain sensitivity
and transiently express the vesicular glutamate transporter,
VGLUT3, which packages glutamate into synaptic vesicles. In
order to determine whether VGLUT3-expressing dorsal horn
neurons convey mechanical pain hypersensitivity, a DREADD
approach was used wherein hM3Dq receptors were specifically
expressed in lamina III of the dorsal horn of Vglut3-Cre mice.
DREADD-induced activation of lamina III VGLUT3-containing
neurons induced mechanical hypersensitivity and allodynia (but
did not affect heat hypersensitivity), an effect that was absent
in mice lacking VGLUT3. Further, the application of CNO to
lamina III neurons prepared from spinal cord slices produced
action potential firing and an inward current, verifying the
specificity of hM3Dq receptors into lamina III dorsal horn
neurons. This is a key finding because it indicates that activating
VGLUT3 neurons in lamina III, a region important for touch
but largely ignored for its role in pain, is sufficient to drive
activity of the downstream circuit that promotes mechanical
allodynia.
There are also spinal circuits within the dorsal horn that
mediate chronic itch, and as such the mechanisms underlying
pain and itch are closely related (Luo et al., 2015). The sensation
of itch is normally suppressed by inputs from mechanoreceptors.
In many forms of chronic itch, including alloknesis, this gating
mechanism is lost. Mice in which dorsal horn neuropeptide Y
(NPY)-derived interneurons are genetically ablated or silenced
with DREADDs develop mechanical itch without an increase
in sensitivity to chemical itch or pain (Bourane et al., 2015).
Specifically, hM4Di:NPY-Cre mice show mechanical itch when
treated with CNO. The itch phenotype dissipates approximately
6 h following CNO injection, which coincides with the
pharmacokinetics of DREADDs.
In another study examining spinal pain circuits, hM4Di
receptor expression was restricted to neurons expressing
transient receptor potential cation channel subfamily V member
1 (TRPV1), an ion channel important for conveying information
regarding heat and pain (Saloman et al., 2015). TRPV1-Cre mice
were used to restrict the transfection of hM4Di receptors to
TRPV1-expressing cells, which include all C-fibers that innervate
the spinal cord. The administration of CNO to hM4Di-TRPV1
mice resulted in a significant thermal analgesic phenotype
that returned to baseline by 5 h post injection. However,
calcium imaging and patch clamp experiments showed that
sensory neurons from hM4Di-TRPV1 mice exhibit decreased
resting intracellular Ca2+ and increased capsaicin-evoked Ca2+
even in the absence of CNO (Saloman et al., 2015). This
CNO-independent effect in neurons from hM4Di-TRPV1 mice
highlights the importance of mechanistic controls in DREADD
studies. In contrast, we are unaware of any major cases in
which the light-activated proteins routinely used for optogenetic
experiments alter cellular properties in absence of light. However,
there are cases in which prolonged light stimulation changes
neuronal function (Herman et al., 2014; Mahn et al., 2016).
For instance, sustained light application on channelrhodopsin 2-
expressing neurons does not inactivate cells, but silences them.
Certain types of cells, most notably interneurons, are particularly
susceptible to this effect, which is termed ‘depolarization block’
(Herman et al., 2014).
DREADDs have also been used to understand the specific
neurons in the brain that control pain responding and output.
Brain structures can modulate incoming sensory information
through a process called descending modulation (i.e., top–down
modulation of pain). Descending inhibition may explain why
soldiers do not appear to be in pain after battlefield injury, but
later report pain after being taken to a hospital. Descending
modulatory pathways can also facilitate pain perception in
certain cases (Fields, 2004). In particular, the periaqueductal gray
(PAG) sends projections to the rostral ventral medulla (RVM),
which transmits these projections via the spinal cord dorsolateral
funiculus to the dorsal horn. Activating hM3Dq receptors in PAG
neurons that contain the dopamine transporter (DAT) resulted
in significant thermal analgesia, while inhibiting PAG neurons
containing GABA did not produce any analgesia (Taylor et al.,
2014). As activation of dopamine neurons in the PAG did not
increase anxiety, these cells may represent a novel target for
treating chronic pain.
Further, in a rodent model of pancreatitis, inhibition
of the paraventricular thalamic nuclei (PVT) with h4MDi
receptors resulted in less pancreatitis-related abdominal pain
and facial expressions (Jurik et al., 2015). DREADD-mediated
PVT inhibition also decreased mPFC activity and increased
RVM activation, pointing toward neuronal engagement of the
descending inhibitory pain pathway (Jurik et al., 2015). There
have only a limited number of studies that use DREADD tools
to investigate the neural circuitry of pain, but these studies have
been elegant and detailed. These reports collectively highlight
the central, yet complex role of nociceptive processes within
the central nervous system, and may stimulate the development
of novel, centrally acting analgesic drugs for persistent pain
conditions.
DREADDs IN ANIMAL MODELS OF
HUMAN DISEASE
DREADD techniques may eventually have uses beyond the
deconstruction of behavior in a laboratory setting. Ultimately,
these tools have considerable potential for the treatment of
psychiatric disorders in humans (Urban and Roth, 2015). Given
the recent demonstration that DREADDs may be expressed and
functional in non-human primates, the possibility that these
receptors can be used to modify behavior in humans now seems
more achievable. Given this therapeutic potential, it is perhaps
not surprising that there has been significant interest in using
DREADD techniques to investigate animal models of human
disease. This section will review recent studies utilizing DREADD
techniques to explore the basis of human diseases, particularly
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those studies focusing on schizophrenia, autism, and Alzheimer’s
disease.
Several groups have investigated the neural mechanisms
underlying the behavioral changes in preclinical models
of schizophrenia (Nguyen et al., 2014; Parnaudeau et al.,
2015; Koike et al., 2016). Schizophrenia is a mental disorder
characterized by abnormal social behavior, delusions, auditory
hallucinations, and cognitive deficits. Abnormalities in
GABAergic transmission, particularly within the vHPC and
mPFC, are thought to contribute to the pathogenesis of the
disorder (Braun et al., 2007). To explore this possibility, Nguyen
et al. (2014) studied the effects of transiently suppressing
the activity of PV-GABA neurons in the vHPC on mouse
behavior. The authors observed that inhibiting PV-GABA
neurons lead to behavioral deficits frequently observed in
animal models of schizophrenia, including reduced pre-pulse
inhibition of the startle response and impaired spontaneous
alternation. In contrast, DREADD inhibition of a more
heterogeneous GABA neuron population, those neurons
expressing glutamic acid decarboxylase 65 (GAD65), resulted
in different behavioral effects. This study highlights the specific
roles that inhibitory neuron subtypes might play in different
symptoms of schizophrenia.
Other studies have showed that cognitive deficits in
schizophrenia, including impaired attention and cognitive
flexibility, may be recapitulated in healthy animals through
inhibition of the mPFC or its afferent targets (Parnaudeau et al.,
2015; Koike et al., 2016). In one recent study, it was shown that
inhibition of the anterior cingulate cortex, a part of the mPFC,
produced a sustained deficit in attention as measured by the
5-choice serial response task (Koike et al., 2016). Additionally,
inhibition of the mediodorsal thalamus, which is connected with
the mPFC, impaired cognitive flexibility. Though DREADD
approaches have been very useful in dissecting the circuitry of
schizophrenia, there has yet to be a conclusive demonstration of
how DREADD-based therapies may treat the symptoms of this
disorder.
DREADD techniques have also been employed to study
autism spectrum disorder (ASD). Notably, ASD is characterized
by impaired social interaction as well as impaired verbal and
non-verbal communication. Recently, the gene CNTNAP2 has
been implicated in ASD, and transgenic mutant mice lacking
CNTNAP2 have been used to model the disorder. CNTNAP2
knockout mice exhibit impaired social behavior, a hallmark
of ASD. This deficit in social behavior was ameliorated by
treatment with oxytocin or the selective activation of oxytocin-
expressing neurons in the paraventricular nucleus of the
hypothalamus using DREADD techniques (Penagarikano et al.,
2015).
Alzheimer’s disease has also been examined using
chemogenetic techniques, though not specifically DREADDs
(Orr et al., 2015). In a recent study, astrocytes were targeted
with chemogenetics because clinical data indicated that
patients with Alzheimer’s disease exhibit increased expression
FIGURE 4 | Behavioral circuitry revealed by DREADD studies in mice. In this schematic of the mouse brain, major brain regions that have been studied using
DREADD technology are illustrated. The specific behavioral functions of these brain regions that have been identified using DREADD technology are indicated in the
linked text.
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levels of Gs-coupled adenosine receptor A2A in these
particular cells. Orr et al. (2015) examined the role of A2A-
receptor expressing cells in learning and memory deficits,
which are commonly observed in Alzheimer’s disease. The
conditional removal of A2A receptors on astrocytes, via
transgenic techniques, enhanced long-term memory in mice.
Conversely, the activation of A2A-receptor expressing cells using
chemogenetic techniques lead to impaired memory performance.
These findings not only identify a contributing factor for
behavioral impairment in Alzheimer’s disease, but also identify
a potential therapeutic strategy. Further, these results stand out
as remarkable as they are one of a few recent cases in which
chemogenetic techniques have achieved therapeutic benefit by
targeting non-neuronal cells (Jain et al., 2013; Scofield et al.,
2015).
DREADD technology has also been applied to the study of
Down Syndrome, a disorder that is associated with an increased
risk for Alzheimer’s disease (Fortress et al., 2015). Notably,
Down Syndrome shares several neuroanatomical features with
Alzheimer’s disease (including microglial activation, β-amyloid
plaques, and neurofibrillary tangles) and also includes memory
impairments (Teipel and Hampel, 2006). Interestingly, previous
studies have shown that the locus coeruleus (LC), the main source
of noradrenergic inputs to the rest of the brain, may be involved
in the pathogenesis of both Down Syndrome and Alzheimer’s
disease (Phillips et al., 2016). Recently, one group investigated
the effects of selectively activating the LC in a mouse model of
Down Syndrome, the Ts65Dn mouse. Ts65Dn mice exhibit a
number of behavioral deficits reminiscent of Down Syndrome,
including impaired working memory and hyperactivity. In this
model, hM3Dq receptors were expressed in neurons of the
LC. Treatment with CNO prior to behavioral testing, which is
expected to activate hM3Dq-LC neurons, improved novel object
recognition and reduced hyperactivity in Ts65Dn mice (Fortress
et al., 2015).
CONCLUSION AND FUTURE
DIRECTIONS
Genetic techniques such as DREADDs and optogenetics are
transforming many areas of neuroscience. In this review, we
have discussed practical applications and highlighted a wide array
of studies that have used DREADDs to deconstruct the neural
circuitry of behavior (summarized in Figure 4) and unravel the
complex mechanisms of disease.
Using DREADDs to determine the contribution of specific
cell types to pathological states may allow for the development
of more rational – and effective – therapies. Ultimately, whether
a DREADD therapeutic approach is appropriate depends upon
the pathology under study. For instance, chronic pain may be
well-suited to treatment through DREADD technology. CNO
is an attractive alternative to current analgesics as it is an
orally available drug, which may silence pain circuits, and
thereby provide pain relief, for prolonged periods. Interestingly,
optogenetics is already being explored as a potential treatment
for pain and other conditions. Two start-up companies (Circuit
Therapeutics and RetroSense Therapeutics) have plans to
begin human trials using optogenetics to treat chronic pain
and genetic blindness, respectively. Early reports indicate that
RetroSense Therapeutics have successfully treated their first
patient. However, such therapies are in their early stages
and it will take considerable refinement before they can
be declared a success. Importantly, optogenetics requires
the implantation of rigid light-emitting devices that could
damage delicate nerve tissue. DREADD-based therapeutic
approaches may be more feasible as such treatments only
require the oral administration of CNO (or another synthetic
drug). Before any DREADD-based therapies become a reality,
however, we must first overcome the significant challenge
of virally expressing designer receptors in adult human
neurons. Only once this barrier has been broken can the
full potential of DREADD-based therapeutic approaches be
explored.
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